药学学报, 2017, 52(1): 120-125
引用本文:
杨雨, 左建, 李家明, 马晓东, 张艳春, 黄伟军. 苯丙烯酰胺类化合物的设计、合成及抗血小板聚集活性[J]. 药学学报, 2017, 52(1): 120-125.
YANG Yu, ZUO Jian, LI Jia-ming, MA Xiao-dong, ZHANG Yan-chun, HUANG Wei-jun. Design, synthesis, and biological evaluation of phenylpropenamides compounds as anti-platelet aggregation[J]. Acta Pharmaceutica Sinica, 2017, 52(1): 120-125.

苯丙烯酰胺类化合物的设计、合成及抗血小板聚集活性
杨雨1,2, 左建1,2, 李家明1,2, 马晓东1,2, 张艳春1,2, 黄伟军1,2
1. 安徽中医药大学药学院, 安徽 合肥 230038;
2. 安徽省中医药科学院药物化学研究所, 安徽 合肥 230038
摘要:
依据拼合原理,设计并合成了20个具有苯丙烯酰胺类结构的化合物,其结构均经IR、1H NMR、13C NMR和MS确证。采用Bron比浊法测定了所有化合物对二磷酸腺苷(adenosine diphoshate,ADP)及花生四烯酸(arachidonic acid,AA)诱导的血小板聚集的抑制活性。初步药理结果显示,化合物6b、9b、9d9h对AA诱导的血小板聚集具有较好的抑制作用;化合物6b、6d、6j、9b9g对ADP诱导的血小板聚集具有较好的抑制作用。
关键词:   
Design, synthesis, and biological evaluation of phenylpropenamides compounds as anti-platelet aggregation
YANG Yu1,2, ZUO Jian1,2, LI Jia-ming1,2, MA Xiao-dong1,2, ZHANG Yan-chun1,2, HUANG Wei-jun1,2
1. College of Pharmacy, Anhui University of Chinese Medicine, Hefei 230038, China;
2. Deparment of Medicinal Chemistry, Anhui Academy of Chinese Medicine, Hefei 230038, China
Abstract:
Twenty phenylpropenamide analogs with structural novelty were designed and synthesized upon pharmacophore-combination strategy. The structures of target compounds were elucidated by IR, 1H NMR, 13C NMR and MS, and all the target compounds were biologically evaluated for the inhibitory activities of platelet aggregation induced by adenosine diphoshate (ADP) and (AA) arachidonic acid via Bron method. As a result, compounds 6b, 9b, 9d and 9h demonstrated potent inhibitory activity against platelet aggregation induced by AA. Meanwhile, compounds 6b, 6d, 6j, 9b and 9g exhibited significant suppression of platelet aggregation induced by ADP.
Key words:   
收稿日期: 2016-10-30
DOI: 10.16438/j.0513-4870.2016-1049
基金项目: 国家创新药物孵化基地项目(2012ZX09401066).
通讯作者: 李家明,Tel:86-551-68129147,Fax:86-551-65169222,E-mail:lijiaming2004@sina.com
Email: lijiaming2004@sina.com
相关功能
PDF(480KB) Free
打印本文
0
作者相关文章

参考文献:
[1] Mega JL, Simon T. Pharmacology of antithrombotic drugs:an assessment of oral antiplatelet and anticoagulant treatments[J]. Lancet, 2015, 386:281-291.
[2] Wang Y, Jie W, Li J, et al. Design, synthesis and pharmacological evaluation of novel piperlongumine derivatives as potential antiplatelet aggregation candidate[J]. Chem Biol Drug Des, 2016, 87:833-840.
[3] Lagerqvist B, Fröbert O, Olivecrona GK, et al. Outcomes 1 year after thrombus aspiration for myocardial infarction[J]. N Engl J Med, 2014, 371:1111-1120.
[4] Goldstein DJ, John R, Salerno C, et al. Algorithm for the diagnosis and management of suspected pump thrombus[J]. Heart Lung Transpl, 2013, 32:667-670.
[5] Kim TH, Kim HM, Park SW, et al. Inhibitory effects of yuzu and its components on human platelet aggregation[J]. Biomol Ther, 2015, 23:149-155.
[6] Gregory YHL, Stephan W, Kurt H, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions[J]. Eur Heart J, 2014, 35:3155-3179.
[7] Ren J, Niu XS, Xiong J, et al. Effects of 1-(cinnamoyl)-4-(phenylethylamine acetyl) piperazine maleate on platelet aggregation and thrombosis[J]. J China Pharm Univ (中国药科大学学报), 2011, 42:458-461.
[8] Zhao LJ, Gao JT, Jin LY. Pharmacological effects and clinical application of cinepazide maleate[J]. J Jilin Med Coll (吉林医药学院学报), 2010, 31:296-299.
[9] Masaya I, Nobuaki O, Satoko O, et al. Piperlongumine, a constituent of Piper longum L., inhibits rabbit platelet aggregation as a thromboxane A2 receptor antagonist[J]. Eur J Pharm, 2007, 570:38-42.
[10] Park BS, Song DJ, Choi WS, et al. Antiplatelet activities of newly synthesized derivatives of piperlongumine[J]. Phytother Res, 2008, 22:1195-1199.